Compare PTCT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | GRFS |
|---|---|---|
| Founded | 1998 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.0B |
| IPO Year | 2006 | N/A |
| Metric | PTCT | GRFS |
|---|---|---|
| Price | $82.28 | $7.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 2 |
| Target Price | ★ $80.65 | $10.15 |
| AVG Volume (30 Days) | ★ 2.2M | 657.9K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | $4.49 |
| Revenue Next Year | $17.70 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $6.96 |
| 52 Week High | $87.50 | $11.14 |
| Indicator | PTCT | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 38.73 |
| Support Level | $73.41 | N/A |
| Resistance Level | $87.27 | $7.73 |
| Average True Range (ATR) | 3.11 | 0.16 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 75.57 | 25.97 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.